[DOI] [PMC free article] [PubMed] [Google Scholar] 205.Murata K, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Takeda S, et al
This announcement from the FDA about Koselugo (selumetinib) is a tremendous step towards our ultimate dream approved treatments for all forms of neurofibromatosis, said Annette Bakker, PhD, President of the Childrens Tumor Foundation
Most adverse effects are gastrointestinal and typically diminish over time as your body adjusts to the medication
Surgery was linked to fewer heart problems, less kidney disease, and even lower rates of diabetes-related eye damage." GLP-1 (glucagon-like peptide-1) receptor agonists are a group of medications commonly prescribed to manage type 2 diabetes and obesity and to lower related health risks
Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency
V.CassidyM.Le JemtelT